Gemcitabine-associated CD8+ CD30+ pseudolymphoma.
We describe a 69-year-old man with a non-small cell carcinoma of the lung, stage III B, who developed bilateral multiple erythematous lesions in the abdominal-inguinal area following treatment with gemcitabine. Histologically, the lesion was characterized by a heavy lymphocytic infiltrate with large CD30+ cells. The lesion was highly suggestive of cutaneous involvement by malignant lymphoma, but complete regression was observed after cessation of gemcitabine. Although rarely reported, gemcitabine therapy can induce skin lesions. Pathologists should be aware of this possibility in order to avoid a misdiagnosis.
Marucci
G
G
Section of Anatomic Pathology, Department of Oncology, University of Bologna, Bellaria Hospital, via Altura 3, 40139 Bologna, Italy.
Sgarbanti
E
E
Maestri
A
A
Calandri
C
C
Collina
G
G
D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D016827:CD8 Antigens / Q000032:analysis; D003841:Deoxycytidine / Q000009:adverse effects* / Q000031:analogs & derivatives*; D003875:Drug Eruptions / Q000209:etiology* / Q000276:immunology / Q000473:pathology; D006801:Humans; D017730:Ki-1 Antigen / Q000032:analysis; D008297:Male; D019310:Pseudolymphoma / Q000139:chemically induced* / Q000276:immunology / Q000473:pathology; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D016827:CD8 Antigens; D017730:Ki-1 Antigen; D003841:Deoxycytidine; D000093542:Gemcitabine